Plasma Cytokines Profile in Patients With Alzheimer’S and Parkinson’S Disease: A Comparative Study in Terms of Inflammation Publisher Pubmed



Shateri S¹ ; Khatami SH¹ ; Haghbin Toutounchi A² ; Rajaei S^{1, 3} ; Mahdavi M¹ ; Mahmoodi Baram S^{1, 3} ; Shahidi GA⁴ ; Habibi AH⁴ ; Aghamollaii V⁵ ; Ghlichnia B⁶ ; Safakish L¹ ; Doagoo A¹ ; Salmani F¹ ; Tafakhori A⁶ Show All Authors Show Affiliations
Source: International Journal of Neuroscience Published:2023

Abstract

Background: Neurodegenerative disorders such as Alzheimer’s and Parkinson’s disease inflict economic and health burdens on societies. Alzheimer’s disease (AD), the most prevalent form of dementia, is accompanied by progressive degradation of memory, decision-making, and judgment. Parkinson’s disease (PD) is characterized by resting tremor, rigidity, bradykinesia, and loss of balance. Extensive research has pinpointed inflammation as a cause of the onset and progression of both diseases. However, it has not been confirmed which one is more formidable in terms of inflammation. Methods: To assess the extent of inflammation that is implicated in AD and PD and answer the question of which one is more inflammatory, serum levels of inflammatory biomarkers, including cytokines, chemokines, and prostaglandin E2 (PEG2), were measured in AD and PD patients as well as a healthy group. Results: Our results showed a significant increase in IL-1α, IL-1β, IL-4, IL-6, IL-10, IL-12p70, IP-10, MCP-1, PEG2, and TNF-α in AD and PD patients compared with the control. Interestingly, IFN-γ did not manifest any significant difference in AD or PD patients compared with the control. Conclusion: As a hallmark of our results, it could be inferred that inflammation, as the underlying etiological cause, plays a more crucial role in PD compared with AD. Based on our results, it is proposed that anti-inflammatory remedies would be putatively more effective in PD rather than AD. © 2023 Informa UK Limited, trading as Taylor & Francis Group.